US Stock MarketDetailed Quotes

CRSP CRISPR Therapeutics

Watchlist
  • 47.010
  • -0.850-1.78%
Close Aug 9 16:00 ET
  • 47.020
  • +0.010+0.02%
Pre 07:25 ET
4.00BMarket Cap-14690P/E (TTM)

CRISPR Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Total revenue
0
0
84,762.39%370M
3,333,233.33%200M
0
44,203.80%70M
56,079.78%100M
-99.95%436K
-99.95%6K
-71.43%94K
Operating revenue
--0
--0
84,762.39%370M
3,333,233.33%200M
--0
44,203.80%70M
56,079.78%100M
-99.95%436K
-99.95%6K
-71.43%94K
Cost of revenue
16.79%52.13M
11.31%46.97M
18.14%130.25M
193.13%20M
-39.73%23.42M
31.58%44.64M
37.68%42.19M
8.97%110.25M
-78.56%6.82M
72.98%38.86M
Gross profit
-305.53%-52.13M
-181.24%-46.97M
318.32%239.75M
2,740.46%180M
39.58%-23.42M
175.12%25.36M
289.73%57.81M
-113.53%-109.81M
65.00%-6.82M
-75.13%-38.77M
Operating expense
-17.79%99.13M
-23.45%93.62M
-17.94%462.29M
-11.47%110.42M
-24.11%108.99M
-19.34%120.59M
-15.95%122.3M
28.51%563.35M
-1.19%124.72M
34.59%143.62M
Selling and administrative expenses
2.36%19.48M
-19.71%17.95M
-25.67%76.16M
-22.16%16.48M
-32.26%18.29M
-27.56%19.03M
-20.20%22.36M
2.78%102.46M
-10.60%21.17M
13.89%27M
-General and administrative expense
2.36%19.48M
-19.71%17.95M
-25.67%76.16M
-22.16%16.48M
-32.26%18.29M
-27.56%19.03M
-20.20%22.36M
2.78%102.46M
-10.60%21.17M
13.89%27M
Research and development costs
-21.06%80.17M
-23.78%76.17M
-16.10%387.33M
-8.12%95.14M
-22.23%90.7M
-17.58%101.56M
-15.48%99.94M
35.55%461.65M
0.45%103.56M
39.67%116.62M
Other operating expenses
---517K
---504K
-58.27%-1.21M
----
----
----
----
59.51%-762K
--0
----
Operating profit
-58.85%-151.26M
-118.01%-140.59M
66.94%-222.54M
152.90%69.58M
27.40%-132.41M
48.04%-95.22M
63.35%-64.49M
-280.22%-673.16M
9.72%-131.54M
-41.55%-182.39M
Net non-operating interest income expense
Other net income (expense)
42.01%26.14M
94.00%24.72M
216.91%71.82M
74.04%20M
184.57%20.67M
419.36%18.41M
3,410.19%12.74M
277.49%22.66M
422.99%11.49M
559.76%7.26M
Other non- operating income (expenses)
42.01%26.14M
94.00%24.72M
216.91%71.82M
74.04%20M
184.57%20.67M
419.36%18.41M
3,410.19%12.74M
277.49%22.66M
422.99%11.49M
559.76%7.26M
Income before tax
-62.88%-125.12M
-123.92%-115.87M
76.83%-150.72M
174.62%89.58M
36.19%-111.74M
57.26%-76.82M
70.53%-51.75M
-271.40%-650.5M
16.34%-120.05M
-37.09%-175.12M
Income tax
39.44%1.29M
-45.15%724K
988.62%2.89M
102.46%233K
171.65%412K
-84.91%923K
-63.41%1.32M
-117.38%-325K
-320.59%-9.48M
3.36%-575K
Net income
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
Net income continuous Operations
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
Minority interest income
Net income attributable to the parent company
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
Basic earnings per share
-52.04%-1.49
-113.43%-1.43
76.79%-1.94
180.14%1.13
37.05%-1.41
59.17%-0.98
71.12%-0.67
-268.21%-8.36
23.37%-1.41
-34.13%-2.24
Diluted earnings per share
-52.04%-1.49
-113.43%-1.43
76.79%-1.94
180.14%1.13
37.05%-1.41
59.17%-0.98
71.12%-0.67
-277.87%-8.36
23.37%-1.41
-34.13%-2.24
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Total revenue 0084,762.39%370M3,333,233.33%200M044,203.80%70M56,079.78%100M-99.95%436K-99.95%6K-71.43%94K
Operating revenue --0--084,762.39%370M3,333,233.33%200M--044,203.80%70M56,079.78%100M-99.95%436K-99.95%6K-71.43%94K
Cost of revenue 16.79%52.13M11.31%46.97M18.14%130.25M193.13%20M-39.73%23.42M31.58%44.64M37.68%42.19M8.97%110.25M-78.56%6.82M72.98%38.86M
Gross profit -305.53%-52.13M-181.24%-46.97M318.32%239.75M2,740.46%180M39.58%-23.42M175.12%25.36M289.73%57.81M-113.53%-109.81M65.00%-6.82M-75.13%-38.77M
Operating expense -17.79%99.13M-23.45%93.62M-17.94%462.29M-11.47%110.42M-24.11%108.99M-19.34%120.59M-15.95%122.3M28.51%563.35M-1.19%124.72M34.59%143.62M
Selling and administrative expenses 2.36%19.48M-19.71%17.95M-25.67%76.16M-22.16%16.48M-32.26%18.29M-27.56%19.03M-20.20%22.36M2.78%102.46M-10.60%21.17M13.89%27M
-General and administrative expense 2.36%19.48M-19.71%17.95M-25.67%76.16M-22.16%16.48M-32.26%18.29M-27.56%19.03M-20.20%22.36M2.78%102.46M-10.60%21.17M13.89%27M
Research and development costs -21.06%80.17M-23.78%76.17M-16.10%387.33M-8.12%95.14M-22.23%90.7M-17.58%101.56M-15.48%99.94M35.55%461.65M0.45%103.56M39.67%116.62M
Other operating expenses ---517K---504K-58.27%-1.21M----------------59.51%-762K--0----
Operating profit -58.85%-151.26M-118.01%-140.59M66.94%-222.54M152.90%69.58M27.40%-132.41M48.04%-95.22M63.35%-64.49M-280.22%-673.16M9.72%-131.54M-41.55%-182.39M
Net non-operating interest income expense
Other net income (expense) 42.01%26.14M94.00%24.72M216.91%71.82M74.04%20M184.57%20.67M419.36%18.41M3,410.19%12.74M277.49%22.66M422.99%11.49M559.76%7.26M
Other non- operating income (expenses) 42.01%26.14M94.00%24.72M216.91%71.82M74.04%20M184.57%20.67M419.36%18.41M3,410.19%12.74M277.49%22.66M422.99%11.49M559.76%7.26M
Income before tax -62.88%-125.12M-123.92%-115.87M76.83%-150.72M174.62%89.58M36.19%-111.74M57.26%-76.82M70.53%-51.75M-271.40%-650.5M16.34%-120.05M-37.09%-175.12M
Income tax 39.44%1.29M-45.15%724K988.62%2.89M102.46%233K171.65%412K-84.91%923K-63.41%1.32M-117.38%-325K-320.59%-9.48M3.36%-575K
Net income -62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M
Net income continuous Operations -62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M
Minority interest income
Net income attributable to the parent company -62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M
Basic earnings per share -52.04%-1.49-113.43%-1.4376.79%-1.94180.14%1.1337.05%-1.4159.17%-0.9871.12%-0.67-268.21%-8.3623.37%-1.41-34.13%-2.24
Diluted earnings per share -52.04%-1.49-113.43%-1.4376.79%-1.94180.14%1.1337.05%-1.4159.17%-0.9871.12%-0.67-277.87%-8.3623.37%-1.41-34.13%-2.24
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --------------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg
Concept ARK Portfolio
ARK Portfolio
Intraday+0.84%
Gene Editing
Gene Editing
Intraday+0.23%